Kami Kim, M.D.
- Professor of Internal Medicine, Division of Infectious Diseases and International Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida (2017-Present).
- Professor of Medicine, Immunology/Microbiology and Pathology, Albert Einstein College of Medicine, Bronx, New York (2002-2017)
- Director of the NIH-funded Training Program in Geographic Medicine and Emerging Infections, Albert Einstein College of Medicine, Bronx, New York (2013-2017)
Area of Special Interest
- Pathogenesis of toxoplasmosis and malaria, parasitic diseases of global significance. Working with clinical investigators at the Blantyre Malaria Project in Malawi to understand the clinical impact of HIV co-infection upon cerebral malaria.
Professional Recognitions & Appointments
- Recipient the National Institute of Allergy and Infectious Disease (NIH-NIAID) National Research Service Award, 1989-1992
- 1993-1996 Recipient of the NIH-NIAID Clinical Investigator Award (K08)
- 1997-2002 Recipient of the National Institutes of Health (NIH-NIAID) Independent Scientist Award (K02)
- 1998-2002 Recipient of the Burroughs Wellcome Fund New Investigator Award in Molecular Parasitology
- 2001-2003 Burroughs Wellcome Fund New Initiatives in Malaria Research Award
- Elected Member, American Society for Clinical Investigation and Association of American Physicians
- Fellow, Infectious Diseases Society of America and American Academy of Microbiology
Published over 100 articles in peer reviewed journals including:
- Rapid Diagnostic Testing of Hospitalized Malawian Children Reveals Opportunities for Improved HIV Diagnosis and Treatment. American Journal of Tropical Medicine and Hygiene - December 2017.
- Linking EPCR-binding PfEMP-1 to brain swelling in pediatric cerebral malaria. Cell Host & Microbe - October 2017.
- Local admixture of amplified and diversified secreted pathogenesis determinants shapes mosaic Toxoplasma gondii genomes. Nature Communications – January 2016
- ELQ-300 prodrugs for enhanced delivery and single-dose cure of malaria. Antimicrobial Agents and Chemotherapy – September 2015
- Inhibition of cytochrome bc1 as a strategy for single-dose, multi-stage antimalarial therapy. American Journal of Tropical Medicine and Hygiene – June 2015
- Harvard University (A.B. Magna Cum Laude)
- Columbia College of Physicians and Surgeons (Medical School)
- Columbia Presbyterian Medical Center (Residency)
- University of California San Francisco (Fellowship –Division of Infectious Diseases)
- San Francisco General Hospital, UCSF (Post Doctoral Fellowship – Parasitology Laboratory)
- Stanford University School of Medicine (Post Doctoral Fellowship - Department of Microbiology & Immunology)